Malaria Treatment Market to nearly reach US$ 3 Billion by 2033; expected to surge at a 5% CAGR | FMI Report

 In 2023, the Malaria Treatment Market is projected to be valued at US$ 1.80 billion, up from US$ 1.72 Billion in the fiscal year 2022. The market is anticipated to increase at a 5% CAGR from 2023 to 2033, reaching US$ 2.93 billion by the end of that year.



According to the Globe Intellectual Property Organization (WIPO), more than 210 million people were affected by malaria in the world in 2019. Malaria is a contagious, sometimes lethal disease. It is caused by Plasmodium, a little parasite that mosquitoes transmit to humans. Malaria may be caused by four different plasmodium species; however, plasmodium falciparum is the one that most often results in fatal cases.

To learn more about this report @ https://www.futuremarketinsights.com/reports/malaria-treatment-market

Due to increased funding from regional governments, the global market for anti-malaria drugs is likewise growing rapidly. This money ought to make it feasible for research companies like Medicines for Malaria Venture to keep looking at potential lead chemicals that might combat malaria. For instance, in November 2017, the US Agency for International Development (USAID) gave US$ 9 million to Medicines for Malaria Venture to be used for three projects: a pharmacovigilance study of Pyramax (pyronaridine-artesunate), a SERC Phase III research to establish a single-exposure revolutionary cure, and a study to evaluate the efficacy of DSM265, a prospective single-exposure radical cure. These improvements are anticipated to drive the global market for malaria therapy.

Region-wise, the MEA will grow with the fastest CAGR during the forecast period. The Middle East and Africa have held the lion's share of the market share and are expected to continue doing so in the future due to the fast rising incidence of malaria in the region. According to the World Health Organization (WHO) report 2021, 241 million cases of malaria were anticipated worldwide in 2020, with 228 million of those cases happening in the WHO African Region. As a result, one of the largest segments of the market for anti-malarial medications is expected to come from the Middle East and Africa. Such developments will bolster the growth from 2023-2033.

Key Takeaways from the Market Study

  • The global malaria treatment market is currently worth more than US$ 1.72 Billion.
  • The oral segment by route of administration is going to occupy a 49% global market share in 2023.
  • The hospital pharmacies segment by distribution channel type will be the fastest growing segment during the forecast period with a 5.4% CAGR.
  • The North American region is predicted to grow with a steady CAGR of 4.6% during 2023-2033.
  • The MEA malaria treatment market is expected to grow with a steady CAGR of 5.5% during 2023-2033.

“Some of the factors driving the market for malaria therapy include the incidence of malarial infection, government initiatives and awareness-raising campaigns, the availability of anti-malarial drugs, and rising healthcare expenditures.” comments a Future Market Insights analyst.

Competitive Landscape

Zydus Healthcare Ltd., Sun Pharmaceutical Industries Ltd., Sanofi SA, GSK Plc, Novartis AG, Cipla Ltd, Viatris Inc., Lupin Ltd, Advacare Pharma USA Llc, and VLP Therapeutics LLC are a few of the well-known companies in the worldwide market for treating malaria.

  • The Gates Foundation-funded Gavi immunization programme introduced the GlaxoSmithKline (GSK) Mosquirix vaccine in three African countries—Kenya, Ghana, and Malawi—in July 2022. The first antimalarial vaccine ever created is allegedly this one. In countries with moderate to high P. falciparum malaria transmission rates, this is an essential initial step in the malaria vaccine deployment.
  • In March 2022, Tafenoquine, a brand-new drug that cures a particular strain of malaria, received a license in Australia from Medicines for Malaria Venture (MMV), which also co-developed the drug with GlaxoSmithKline (GSK) for use in children and teenagers. The drug is coupled with chloroquine, a popular anti-malarial drug.

Key Segments Covered in the Malaria Treatment Market Report

Malaria Treatment Market by Treatment:

  • Prescription Medications
  • Vaccines
  • Diagnostic Tests
  • Others

Malaria Treatment Market by Drug Type:

  • Branded
  • Generic

Malaria Treatment Market by Route of Administration:

  • Oral and Parenteral
  • Intravenous

Malaria Treatment Market by Distribution Channel:

  • Direct Tender
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Malaria Treatment Market by End User:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Comments

Post a Comment

Popular posts from this blog

Monoclonal Antibodies Market to touch US$ 647.01 Billion by 2032; applications abound in Oncology | FMI Report

Image
  Monoclonal Antibodies Market is projected to increase at a CAGR of 12% during the forecast period between 2022 and 2032, reaching a total of US$ 647.01 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6.1%. Human mAbs offer efficient modulation in effector functions and are less immunogenic as compared to chimeric or humanized mAbs. Such antibodies can be produced through the use of phage display and hybridoma technologies in transgenic mice. As a result, with recent technological progress in genetic engineering, the production of fully human mAbs is anticipated to gain traction in the near future.  Get Full Access @ https://www.futuremarketinsights.com/reports/monoclonal-antibodies-market North America recorded the largest market share of 46.2% in 2021 due to the presence of a highly developed healthcare infrastructure, high patient awareness, and growth in cancer re...
Read more

Hospital Consumables Market is expected to reach valuation of US$ 853.2 Billion | FMI

  According to Future Market Insights' newly released Hospital Consumables market analysis report, global Hospital Consumables market sales in 2021 are expected to be US$ 346 billion. The estimated market growth of 12.5% between 2022 and 2032 is expected to be much greater than the previous trend. The consumables market is estimated to have a total revenue opportunity of US$ 853.2 billion. The increase in chronic diseases, medical operations, and the expanding older population are driving market expansion. To learn more about this report @ https://www.futuremarketinsights.com/reports/hospital-consumables-market With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis on Hospital Consumables market. FMI offers insights into the market data on over 5000+ drugs for more than 100 countries, which further aids the research on current and upcoming market scenario for the Hospita...
Read more

Oral Solid Dosage Pharmaceutical Formulation Market is expected to reach US$ 1.0 Billion by 2032

Image
  Demand for the global oral solid dosage pharmaceutical formulation market is anticipated to expand at a robust CAGR of 6.4% over the valuation period from 2022 to 2032. The global market is expected to touch US$ 555.3 Million by 2022 and surpass a valuation of US$ 1.0 Billion in 2032. As per the studies, on the basis of dosage, the tablets segment led to the market with a massive share of around 53.1% in 2021. As per Future Market Insights analysis, the oral solid dosage pharmaceutical formulation market accounted for around 1.4% of the overall US$ 40.0 Billion of the global pharmaceutical drug delivery market in 2021. The expansion of sales of solid dosage pharmaceutical formulations was anticipated at a robust rate of 8.1% from 2012 to 2021, attributed to the surging adoption and greater patient compliance. Get Full Access @ https://www.futuremarketinsights.com/reports/oral-solid-dosage-pharmaceutical-formulation-market Oral solid dosages are one of the most commonly uti...
Read more